Teva Pharmaceutical Industries (NYSE:TEVA) CAO Sells $371,460.00 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) CAO Amir Weiss sold 12,300 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the transaction, the chief accounting officer directly owned 5,650 shares in the company, valued at approximately $170,630. The trade was a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock traded up $0.22 during midday trading on Thursday, hitting $30.28. The stock had a trading volume of 8,057,732 shares, compared to its average volume of 11,753,719. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $30.44. The company has a market capitalization of $34.73 billion, a PE ratio of 50.47, a P/E/G ratio of 1.79 and a beta of 0.67. The firm’s fifty day moving average is $24.03 and its two-hundred day moving average is $19.88. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Large investors have recently made changes to their positions in the company. Cromwell Holdings LLC lifted its position in shares of Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after buying an additional 629 shares in the last quarter. Advisors Asset Management Inc. bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $41,000. Rothschild Investment LLC increased its stake in Teva Pharmaceutical Industries by 97.0% in the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after acquiring an additional 1,348 shares during the last quarter. JFS Wealth Advisors LLC raised its holdings in shares of Teva Pharmaceutical Industries by 257.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock worth $56,000 after acquiring an additional 2,000 shares in the last quarter. Finally, LRI Investments LLC boosted its position in shares of Teva Pharmaceutical Industries by 246.0% during the 3rd quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock valued at $57,000 after acquiring an additional 2,000 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

TEVA has been the topic of several recent analyst reports. UBS Group raised their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Barclays initiated coverage on Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 price target on the stock. Scotiabank began coverage on Teva Pharmaceutical Industries in a research note on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 price objective for the company. Bank of America increased their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $31.13.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.